Journal of Clinical Investigation - Cardiology

SEPTEMBER 3, 2024

Obesity is a known driver of endometrial cancer. In this issue of the JCI, Gómez-Banoy and colleagues investigated a cohort of patients with advanced endometrial cancer treated with immune checkpoint inhibitors targeting the interaction between programmed cell death receptor-1 (PD-1) and its ligand (PD-L1).

Cancer 63

Cancer Obesity BMI Biomarkers 63

Frontiers in Cardiovascular Medicine

DECEMBER 13, 2023

LH individuals also appear to have more cardiovascular disease (CVD) related conditions like diabetes and cancer. FMD was significantly ( p  = 0.043) lower in LH (6.1% ± 3.2%) compared to RH (7.6% ± 3.8%), independent of age, sex, race, BMI, and HDL. Additionally, SDNN was lower ( p  = 0.041) in LH (47.4 ± 18.8 ms)

Cardiovascular Disease 109

Cardiovascular Disease BMI Laboratory Cancer 109

DAIC

FEBRUARY 1, 2024

QRISK incorporates factors such as blood pressure, cholesterol, BMI, smoking status, age, sex, and family history to estimate risk. About PRS Genetics is an important risk factor for many common diseases like CVD, and others including diabetes, osteoporosis, and common cancers like breast , prostate , and bowel cancer.

Cardiovascular Disease 110

Cardiovascular Disease Risk Factors Best Practices Cholesterol 110

Dr. Paddy Barrett

MARCH 23, 2024

It’s not that they don’t get cardiovascular disease, cancer or dementia; they just get it way later than everyone else. When broken down by disease category, cardiovascular disease, cancer, dementia, stroke, osteoarthritis, hypertension and stroke, the pattern is the same. J Gerontol A Biol Sci Med Sci.

Chronic Disease 106

Chronic Disease Quality of Life Dementia Cancer 106

Dr. Paddy Barrett

JANUARY 16, 2024

Cardiovascular disease, cancer and dementia account for 60% of all deaths in the US. Let’s start with Cancer. Compared to those who had ‘Low’ lifestyle scores, those with ‘Ideal’ scores were 27% less likely to be diagnosed with cancer in the next ten years. The leading causes of death are clear.

Cancer 97

Cancer Dementia Diabetes Cardiovascular Disease 97

DAIC

MARCH 8, 2024

The estimated relative risk reduction of MACE was 20% vs placebo (HR 0.80 [95% CI: 0.72, 0.90] p 1,2 The reduction of MACE with Wegovy was not impacted by age, sex, race, ethnicity, baseline BMI, or level of renal function impairment. These may be symptoms of thyroid cancer. in patients randomized to Wegovy 2.4 mg and 36.4%

Obesity 111

Obesity Heart Disease Heart Attack Heart attacks 111

DAIC

MARCH 5, 2024

They adjusted for the participants' use of tobacco and other characteristics, including their age, sex, race, body mass index or BMI, obesity, diabetes, physical activity levels, and socioeconomic status. For a more complete funding disclosure and list of authors, please see the full JAHA research article.

Heart Attack 98

Heart Attack Heart attacks Stroke Strokes 98

Frontiers in Cardiovascular Medicine

DECEMBER 15, 2024

Osimertinib is first-line treatment for epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) and has been associated with cardiotoxicity. BMI was identified as a potentially modifiable risk factor for osimertinib-associated cardiotoxicity, worthy of further study. Following osimertinib (vs. vs. 5.3%; p=.046).

Cancer 52

Cancer Electrocardiogram Risk Factors BMI 52